跳转至内容
Merck
CN

G7048

Sigma-Aldrich

氯胍 盐酸盐

≥95% (HPLC)

别名:

Chlorguanide, N1-(4-Chlorophenyl)-N5-isopropylbiguanide

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C11H16ClN5·HCl
化学文摘社编号:
分子量:
290.19
EC 号:
MDL编号:
UNSPSC代码:
51101906
PubChem化学物质编号:
NACRES:
NA.77
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

质量水平

方案

≥95% (HPLC)

表单

solid

储存条件

desiccated

溶解性

acetonitrile: water: ~1 mg/mL (60/40)

创始人

AstraZeneca

储存温度

2-8°C

SMILES字符串

Cl.CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1

InChI

1S/C11H16ClN5.ClH/c1-7(2)15-10(13)17-11(14)16-9-5-3-8(12)4-6-9;/h3-7H,1-2H3,(H5,13,14,15,16,17);1H

InChI key

SARMGXPVOFNNNG-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

应用

Proguanil (chlorguanide) may be used in anti-parasitic protozoan drug development to study its pharmacokinetics, metabolism, safety, efficacy and methods of delivery as an antimalarial drug.

生化/生理作用

Chlorguanide (proguanil) is combined with atovaquone for malaria prophylaxis. The two compounds act synergistically to inhibit the plasmodial dihydrofolate reductase (DHFR) and interrupt the electron transport chain. Mutations in DHFR account for the development of resistant strains.
Proguanil hydrochloride is antimalarial. Dihydrofolate reductase inhibitor

特点和优势

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形图

Skull and crossbones

警示用语:

Danger

危险声明

危险分类

Acute Tox. 3 Oral

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Rachida Tahar et al.
Acta tropica, 125(2), 214-219 (2012-10-23)
Rapid diagnostic tests (RDTs) are affordable, alternative diagnostic tools. The present study aimed to evaluate RDTs available in Cameroon and compare their characteristics to follow the parasitological response of patients for 28 days. Malaria diagnosis was assessed in 179 febrile
Nicholas Fisher et al.
The Journal of biological chemistry, 287(13), 9731-9741 (2012-01-28)
Atovaquone is an anti-malarial drug used in combination with proguanil (e.g. Malarone(TM)) for the curative and prophylactic treatment of malaria. Atovaquone, a 2-hydroxynaphthoquinone, is a competitive inhibitor of the quinol oxidation (Q(o)) site of the mitochondrial cytochrome bc(1) complex. Inhibition
Carine Van Malderen et al.
Malaria journal, 11, 139-139 (2012-05-02)
Malaria is a leading cause of mortality, particularly in sub-Saharan African children. Prompt and efficacious treatment is important as patients may progress within a few hours to severe and possibly fatal disease. Chlorproguanil-dapsone-artesunate (CDA) was a promising artemisinin-based combination therapy
Miriam K Laufer et al.
PloS one, 7(8), e42284-e42284 (2012-08-23)
The predominance of chloroquine-susceptible falciparum malaria in Malawi more than a decade after chloroquine's withdrawal permits contemplation of re-introducing chloroquine for targeted uses. We aimed to compare the ability of different partner drugs to preserve chloroquine efficacy and prevent the
Allan Pamba et al.
Blood, 120(20), 4123-4133 (2012-09-21)
Drug-induced acute hemolytic anemia led to the discovery of G6PD deficiency. However, most clinical data are from isolated case reports. In 2 clinical trials of antimalarial preparations containing dapsone (4,4'-diaminodiphenylsulfone; 2.5 mg/kg once daily for 3 days), 95 G6PD-deficient hemizygous

商品

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持